The money will start human trials on the device, called CardioARM, and complete a commercial product to be submitted for both U.S. and European approval. Cardiorobotics thinks its slender winding robot that remembers its path through the body can by used in an array of surgical procedures. But CardioARM itself could be used in up to 1 million relevant cardiac procedures a year, including ablations.